Impact on Daily Practice Is Completely Unknown

Article

For independent physician practices, the realities of overhead expenses, time available for patient care, and regulatory requirements can only be assessed when the specific requirements for reporting and reimbursement are clear.

Array

Recent Videos
7 experts are featured in this series.
7 experts are featured in this series.
2 KOLs are featured in this series.
Patients with high-risk markers may especially benefit from the addition of daratumumab to lenalidomide as maintenance therapy for NDMM.
A machine learning method for scoring tumor-infiltrating lymphocytes may address variability in pathologist measurements.
Clinical trials in small cell lung cancer appear to be more “pragmatic” with their inclusion criteria than before, according to Anne Chiang, MD, PhD.
Related Content
While metastasis-directed therapy has shown it may be a tool for prolonging PFS in other research, progression does still occur in most patients.

Adding 177Lu-PNT2002 to SBRT Improves PFS in Oligorecurrent Prostate Cancer

Tim Cortese
September 29th 2025
Article

The addition of 177Lu-PNT2002 did not significantly increase toxicity in patients with oligorecurrent prostate cancer who received SBRT.

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC

Gary Steinberg, MD
September 29th 2025
Podcast

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

The 2-year rates for disease-free survival in the radiation and observation arms, respectively, were 71.6% vs 58.7%.

Adjuvant Radiation Therapy Improves Local Survival in High-Risk MIBC

Roman Fabbricatore
September 29th 2025
Article

No toxicity-related discontinuations were seen with adjuvant radiotherapy among patients with muscle-invasive bladder cancer.

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

The administration of proton beam therapy requires less specialized training but is also more expensive.

Proton Beam Therapy and IMRT Confer Similar AEs and QOL in Oropharyngeal Cancer

Ariana Pelosci
September 29th 2025
Article

Regarding feeding tube use and weight loss, patients with oropharyngeal cancer treated with proton beam therapy or IMRT saw similar results.

Acknowledging Mortality and Death in Cancer Care

Acknowledging Mortality and Death in Cancer Care

Ariana Pelosci
September 29th 2025
Article

In the oncology setting, having discussions about mortality and death may be daunting for patients, but is vital and inevitable.